DVA · DaVita Inc. · Stock research

Current Thesis

The $175 weekly-close condition flagged in the 2026-08-08 note came and went. DVA closed Friday 2026-08-21 at $173.82, 27.9% below the $240.96 52-week high, with RSI(14) at 10.9 — down from 19.7 two weeks earlier. Nothing company-specific was announced or filed between the 2026-08-04 Q2 print and that close: the company's public news and filing feed shows the 08-04 results release as the most recent item. So the additional slide is the market continuing to mark down the H2 revenue-per-treatment guide, with no new information to argue about. The census-recovery re-rate that carried this name off the $103.87 52-week low is finished as a narrative leg. What is left is a cash-generative dialysis operator trading below the lowest end of some published target ranges, with the sell-side mean still sitting far above spot — a configuration where the marks, not the price, are the stale number. The shares are down 12.4% over three months.

Bullish and bearish views on DaVita Inc.

The model's bull view on DaVita Inc. (DVA), in brief: management moved FY treatment growth to the top end of the 25–50bps range (2026-08-04 release and call). The bear view: The 2026-08-05 session was a break, not a wobble. Both cases follow in full.

Bull Case

• management moved FY treatment growth to the top end of the 25–50bps range (2026-08-04 release and call). Census ~298,500 patients across 3,266 outpatient centers.
• Share count is shrinking into the drawdown. 2.2M shares repurchased for $348M in Q2, $751M year to date, against an FY free-cash-flow guide of $1.0–1.25B (2026-08-04). At the 2026-08-21 close of $173.82, the same dollar retires materially more stock than at the pre-print level near $228 (Simply Wall St, 2026-08-05).
• Both lines beat. Adjusted EPS $4.02 versus $3.88 consensus; revenue $3.554B versus $3.496B (2026-08-04).
• Published targets sit above spot. TD Cowen upgraded to Buy with a $220 target (2026-08-05); Barclays raised to $224 the same day; Truist held at $215, cut from $250. Aggregations as of 2026-08-20 show a mean near $214.83 across 6 analysts and $218.43 across 7, range $165–$270.
• No visible new insider supply. As a >10% holder Berkshire discloses DVA sales on Form 4 within days; the public filing feed showed no DVA Form 4 between 2026-08-04 and 2026-08-21. Absence of a filing is weaker evidence than a filing, but it is the observable.

Bear Case

• The 2026-08-05 session was a break, not a wobble. Prior close near $228 to roughly $189 — a 17% single-day decline (Simply Wall St, 2026-08-05) — on an earnings beat. The market rejected an FY26 adjusted EPS range affirmed at $14.10–$15.20 (midpoint $14.65) against $14.82 consensus.
• Revenue per treatment went backwards. $415.87 in Q2 versus $417.59 in Q1; FY RPT growth guided 1–2%, which management said implies slightly negative year-over-year RPT in H2 on declining ACA-driven commercial mix and lower phosphate-binder revenue (2026-08-04 call).
• Costs are running ahead of the guide. Simply Wall St's 2026-08-05 read of the Q2 disclosure puts year-to-date patient care cost growth above 3% against an FY expectation of 1.25–2.25%, with quarterly interest expense of $152M and net leverage at 3.37x. H2 has to decelerate on costs for the operating-income guide of $2,150–2,250M to hold.
• Every shelf named in prior coverage is gone. The $203 June breakout level went in the print week; $175 went on the 2026-08-21 weekly close. RSI(14) at 10.9 describes near-continuous distribution over three weeks.
• One published target is already under spot. The $165 low in the 2026-08-20 aggregated range sits below the $173.82 close, and two of the three post-print analyst actions on 2026-08-05/07 were target cuts.

Setup & Price Structure

The 2026-08-21 close of $173.82 sits inside a 52-week range of $103.87–$240.96. The overhead structure is the 2026-08-05 gap from roughly $228 to $189; nothing has traded back into it in the eleven sessions since. RSI(14) of 10.9 is an extreme reading — worth naming as a description of how one-sided the tape has been, not as a signal that a low is in. No base has formed: the last identifiable horizontal shelf below spot is unbuilt, and the first serious reference beneath is the $165 low target.

The narrative is dead. The dating is specific — 2026-08-05 (17% single-day break on a beat), 2026-08-07 (targets marked down to $215/$220 from levels that had been below the pre-print price), and 2026-08-21 (weekly close through the $175 floor named in the prior note). Narrative failed and structure broken are both satisfied on the tape.

Crowding and positioning observables, stated as observables: there is no imminent earnings date — DaVita had not scheduled a Q3 call as of 2026-08-21, and recent years put Q3 in late October. Price is below, not extended above, any rising moving average, so the usual overbought-distance measure does not apply here. The company is retiring stock rather than issuing it ($348M in Q2). Insider supply from the largest holder is disclosed near real time and none appeared in the drawdown window. Retail-facing coverage clusters around value screens ("strong ROE", "21% potential upside", directorstalkinterviews.com pieces dated August 2026) rather than momentum, which is what late-drawdown coverage typically looks like.

Catalyst Calendar (next 30 days)

• 2026-08-22 to 2026-09-21 — nothing scheduled. No company event, no print, no rule-making deadline falls inside the window. The 2026-08-14 Q2 13F deadline has passed and its read-through was always limited, since Berkshire discloses DVA sales on Form 4 well ahead of any 13F.
• ~2026-10-07 to 2026-10-14 (est.) — historical timing for the company to announce its Q3 conference-call date. Outside the window.
• ~2026-10-28 (est.) — Q3 2026 print. Outside the window; it is the first hard datapoint on the H2 RPT question.
• ~2026-10-31 (est.) — CMS ESRD PPS CY2027 final rule. Outside the window.
• 2026-11-01 — ACA marketplace open enrollment for plan year 2027 begins. Outside the window, but it is the direct input into the commercial-mix variable management named on 2026-08-04.

What Would Change Our Mind

The structural argument that has already failed is the $175 floor: it broke on the 2026-08-21 weekly close, which is the outcome the 2026-08-08 note said would reframe this as a de-rating rather than a print-reaction overshoot. That reframe is now the working read, and it breaks in either direction on observable conditions.

Downside confirmation: a weekly close below $165 would take price under the lowest published 12-month target in the 2026-08-20 aggregated range and put the drawdown deeper than the 2026-08-05 gap low without any new information to explain it. A secondary condition is fundamental: FY26 adjusted EPS revised below the $14.10 low end at the Q3 print (~2026-10-28, est.), or Q3 revenue per treatment printing under the Q2 $415.87.

Upside repair: a weekly close back above $189 would put price inside the 2026-08-05 gap and argue the mark-down is complete. Confirming fundamentals would be Q3 RPT flat-to-up sequentially, adjusted operating income tracking above the pace required for the $2,150M low end, and a raise off the $14.65 midpoint. A resumption of Berkshire Form 4 sales below the ~28.7M shares disclosed 2026-08-04 would work against that repair by adding supply into it.

Correlation Notes

• Beta ~0.84–0.91. A defensive, low-volatility operator whose re-ratings come from prints and estimate revisions rather than tape velocity; the 17% single-day move on 2026-08-05 is far outside that behaviour and was event-driven.
• Commercial-mix exposure links DVA to ACA marketplace enrollment, a variable shared with managed-care insurers. Management named declining ACA enrollment as a driver of the Q2 sequential RPT decline on 2026-08-04, so 2027 open-enrollment data (from 2026-11-01) is a shared read-through.
• Fresenius Medical Care is the only comparable listed dialysis operator. Prior coverage flagged the absence of a sympathetic peer bid through this drawdown; that has not changed on any dated evidence through 2026-08-21.
• The Berkshire repurchase agreement mechanically ties buyback size to the 45% stake cap. The 2026-05-01 open-market sale of 1,220,376 shares at an average $149.84 lowered the stake to 44.9% under that agreement, so the buyback and the largest holder's supply are linked rather than independent.
• CMS ESRD PPS rate-setting is a policy factor common to every US dialysis provider, which is why the CY2027 final rule (~2026-10-31, est.) is a sector event rather than a company-specific one.